Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Umesh GangishettiJ Christina HowellRichard J PerrinNatalia LounevaKelly D WattsAlexander KollhoffMurray GrossmanDavid A WolkLeslie M ShawJohn C MorrisJohn Q TrojanowskiAnne M FaganSteven E ArnoldWilliam T HuPublished in: Alzheimer's research & therapy (2018)
CSF proteins associated with AD clinical stages and progression can complement Aβ and tau markers to inform neurodegeneration. A validated panel inclusive of multiple biomarker features (etiology, stage, progression) can improve AD phenotyping along the A/T/N framework.